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The aim of this study was to identify a biomarker that could improve alpha-fetoprotein
(AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with
cirrhosis. We performed proteomic proﬁling of plasma from patients with cirrhosis or
HCC and validated selected candidate HCC biomarkers in two geographically distinct
cohorts to include HCC of different etiologies. Mass spectrometry proﬁling of highly frac-
tionated plasma from 18 cirrhosis and 17 HCC patients identiﬁed osteopontin (OPN) as
signiﬁcantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were
subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cir-
rhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy con-
trols in two independent cohorts. OPN plasma levels were signiﬁcantly elevated in HCC
patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN
alone or in combination with AFP had signiﬁcantly better area under the receiver operat-
ing characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both
cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and
the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC.
OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study includ-
ing 22 patients who developed HCC during follow-up, OPN was already elevated 1 year
before diagnosis. Conclusion: OPN was more sensitive than AFP for the diagnosis of HCC
in all studied HCC groups. In addition, OPN performance remained intact in samples col-
lected 1 year before diagnosis. (HEPATOLOGY 2012;55:483-490)
H
epatocellular carcinoma (HCC) is an increas-
ingly prevalent clinical problem worldwide
and is the third most common cause of can-
cer-related death.1 Cirrhosis of any etiology is the
most common risk factor for HCC development. Over
90% of HCCs develop on a cirrhotic liver resulting
from either chronic hepatitis B virus (HBV) or hepati-
tis C virus (HCV) infections, alcohol abuse, or accu-
mulation of fat referred as nonalcoholic steatohepati-
tis.2-4 Patients at risk for developing HCC should be
entered into surveillance programs. Alpha-fetoprotein
(AFP) is widely used as a surveillance and detection
test for HCC among patients with cirrhosis, despite
its limited performance, particularly in early-stage
HCC.2,5-7 Apart from AFP, other markers (e.g., lectin-
bound AFP [AFP-L3], des-gamma carboxyprothrom-
bin [DCP], and glypican-3) have been proposed for
HCC detection.8-10 However, recent studies showed
that neither DCP nor AFP-L3 presented better per-
formance characteristics than AFP for the diagnosis of
early-stage HCC,11 and that neither DCP nor AFP is
optimal to complement ultrasound in the detection of
early HCC.12 Development of novel biomarkers for
the early detection of HCC thus remains an impor-
tant target before a breakthrough appears on HCC
surveillance and early intervention. The aim of this
study was to identify, using a proteomic approach, a
biomarker that could improve AFP performance as a
surveillance test for HCC among patients with
cirrhosis.
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Patients and Methods
Study Design and Patient Characteristics. Plasma
samples were collected following informed consent
from patients enrolled at the University of Michigan
(Ann Arbor, MI) (Cohort 1) and from patients en-
rolled at the Cancer Control Unit of the National
Cancer Institute of Thailand, Bangkok (Cohort 2).
Assays were performed at the Fred Hutchinson Cancer
Research Center (Seattle, WA). The study was per-
formed in compliance with and after approval from
the respective institutional review boards of all sites. At
the University of Michigan, HCC was diagnosed
according to the American Association for the Study
of Liver Diseases (AASLD) guidelines.5 Early-stage
HCC was deﬁned as Barcelona Clinic Liver Cancer
staging system (BCLC) stage A, according to AASLD
guidelines, and cirrhosis was deﬁned as previously
described.11 At the National Cancer Institute (NCI) of
Thailand, HCC diagnosis was based on a clinical algo-
rithm, including imaging (i.e., ultrasonography [US]
and computerized tomography) and biochemistry (i.e.,
AFP and liver-function enzyme testing). A previous
study on patients from the NCI of Bangkok has shown
that this diagnosis algorithm is over 95% speciﬁc
against histopathology for detection of HCC in this
context.13 A total of 312 patients, including 131
patients with HCC and 96 with cirrhosis, were selected
from the two cohorts for this study. The characteristics
of these patients are shown in Supporting Table 1.
Plasma Proteomic Proﬁling. Plasma was immuno-
depleted of human albumin, transferrin, immunoglob-
ulin, antitrypsin, and haptoglobin using the Multiple
Afﬁnity Removal Column (Agilent Technologies, Santa
Clara, CA), and proteins from the immunodepleted
fractions were separated using the Alliance 2-D Biose-
parations System (Waters Corporation, Milford, MA).
The resulting protein fractions were further separated
by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Gels were stained with
colloidal Coomassie blue G-250, and each lane was
cut into pieces. Gel pieces were destained and digested
by trypsin to generate peptide solution. The generated
peptide samples were analyzed by liquid chromatogra-
phy/electrospray ionization/tandem mass spectrometry
(MS/MS), equipped with a two-dimensional (2D)
nano-HPLC (high-performance liquid chromatogra-
phy) device (Eksigent, Dublin, CA) coupled to a
hybrid LTQ-OrbiTrap (Thermo Scientiﬁc, Waltham,
MA) mass spectrometer. The raw data ﬁle was con-
verted to the m/z XML generic format and searched
against the human International Protein Index protein
sequence database using the X!Tandem Search Engine.
To obtain reliable protein identiﬁcations from the
search results, PeptideProphet and ProteinProphet, sta-
tistical tools that compute peptide and protein proba-
bilities based on peptides assigned to MS/MS spectra,
were used. Protein abundance was calculated as a func-
tion of the total number of spectra assigned to the
protein.
Enzyme-Linked Immunosorbent Assay. Plasma
levels of osteopontin (OPN) were measured using a
commercial enzyme-linked immunosorbent assay kit
(R&D Systems, Inc., Minneapolis, MN) and 50 lL of
diluted (1:100) plasma samples. Samples were added
to the plates precoated with the OPN antibody ﬁrst
and incubated for 2 hours at room temperature. After
four washes, 200 lL of the OPN antibody conjugated
to horseradish peroxidase were added and incubated for
2 hours at room temperature. After four washes, 200
lL of tetramethylbenzidine substrate solution were
added and incubated for 30 minutes in the dark, fol-
lowed by the addition of 50 lL of stop solution. Ab-
sorbance was measured at 450 nm with wavelength cor-
rection at 540 nm, using a SpectraMax Plus384
spectrophotometer (Molecular Devices, Sunnyvale, CA).
Statistical Analysis. To summarize test performance
on the whole range of thresholds, receiver operating
characteristic (ROC) curves were plotted for each bio-
marker test. Area under the ROC curve (AUC) was
calculated, and its 95% conﬁdence interval (CI) was
calculated via 1,000 bootstrap samples. We calculated
the optimal cutoffs using the maximum sum of sensi-
tivity and speciﬁcity as well as using the minimum dis-
tance to the top-left corner of the ROC curve. The
complementary property of OPN to AFP for the
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diagnosis of HCC was illustrated by comparing ROC
curves using the ‘‘or’’ rule of a logistic regression with
OPN and AFP in the model to that with only AFP in
the model (i.e., predictor is coded as 1 if either AFP
or OPN is above its respective prespeciﬁed threshold).
All analyses were repeated after stratifying the samples
for viral etiology, AFP levels, and HCC stage. Sensitiv-
ity and speciﬁcity and their 95% CIs were calculated
for AFP and OPN. Differences of sensitivities and spe-
ciﬁcities for differentiating HCC and cirrhotic controls
between OPN and AFP and their 95% CIs were calcu-
lated using 1,000 bootstrap samples.
Results
MS Proﬁling Identiﬁed Higher Plasma Levels of
OPN in HCC Patients, Compared to Patients With
Cirrhosis. Extensive MS analysis after a multidimen-
sional protein separation strategy composed of 2D
HPLC, followed by SDS-PAGE, was applied to
plasma samples collected from 17 patients with HCC
and 18 with liver cirrhosis. To reduce variability, all
selected patients were male, with AFP values below 20
ng/mL. OPN was identiﬁed by MS with high conﬁ-
dence, based on the assignment of 12 unique peptides
resulting in 40.4% coverage of the sequence (Fig. 1A).
Though OPN was detected in the majority (81%) of
the samples analyzed, the number of peptide hits
assigned to OPN was signiﬁcantly higher in HCC
plasma (mean ¼ 22.12), compared to cirrhosis plasma
(mean ¼ 2.5) (P ¼ 0.03), indicative of higher OPN
levels in the plasma of patients with HCC (Fig. 1B).
Circulating OPN Levels in HCC Patients From
Cohort 1. We ﬁrst analyzed OPN levels in a cohort
(Cohort 1) established in the United States and includ-
ing a majority of HCC and cirrhosis patients with
CHC (55% and 59%, respectively) and a majority
(60%) of early-stage HCC (Table 1). OPN levels were
measured blinded to clinical data in a total of 173
plasma samples collected from 40 HCC patients, 73
cirrhosis patients, 32 with CHC, and 28 healthy con-
trols. Plasma levels of OPN were signiﬁcantly higher
in HCC plasma (mean ¼ 271.4 ng/mL) than in cir-
rhosis (mean ¼ 86.2 ng/mL; P < 0.0001), CHC
(mean ¼ 52.6 ng/mL; P < 0.0001), and healthy con-
trols (mean ¼ 32 ng/mL; P < 0.0001) (Fig. 2).
Performance of OPN in Cohort 1. We further
evaluated the performance of OPN in discriminating
HCC and cirrhosis patients in Cohort 1. The AUC
for OPN (0.76; 95% CI: 0.66-0.85) was higher than
for AFP (0.71; 95% CI: 0.60-0.82) (Fig. 3A). The
combination of OPN and AFP further increased the
AUC (0.82; 95% CI: 0.73-0.91). When only HCV-
associated HCCs were compared with HCV-associated
cirrhosis, the AUC for AFP decreased (0.64; 95% CI:
0.49-0.80), whereas OPN had an even higher AUC
(0.80; 95% CI: 0.69-0.91) (Fig. 3B). For HCV
patients, the addition of AFP to OPN only marginally
increased the AUC for OPN alone (0.81; 95% CI:
0.7-0.93). When only early-stage HCCs, deﬁned in
this study as BCLC stage A, were compared with cir-
rhosis, OPN had, again, a higher AUC (0.73; 95%
CI: 0.62-0.85) than AFP (0.68; 95% CI: 0.54-0.82)
(Fig. 3C). The combination of OPN and AFP further
increased the AUC (0.81; 95% CI: 0.70-0.91). Finally,
when only HCC with AFP levels below 20 ng/mL
were included, OPN AUC remained high (0.75; 95%
CI: 0.64-0.87), whereas, as expected, AFP AUC was
low (0.59; 95% CI: 0.43-0.76) (Fig. 3D).
The performance of OPN in these patient groups is
further described in Table 1. When using the currently
recommended clinical cutoff for AFP (20 ng/mL) and
the best cutoff for OPN determined using the minimal
distance to the top-left corner in the ROC curve (91
ng/mL), OPN had a better performance than AFP,
with a sensitivity of 74% (95% CI: 60-88), compared
Fig. 1. OPN identiﬁcation by MS in plasma from patients with cir-
rhosis or HCC. (A) OPN was identiﬁed by MS with 12 unique peptides,
leading to 40.4% sequence coverage. (B) OPN abundance was higher
in plasma of patients with HCC, compared to plasma of patients with
cirrhosis (P ¼ 0.03). OPN abundance is shown as the total number of
MS/MS spectra assigned to that protein in each sample.
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to 53% (95% CI: 37-69) for AFP. When AFP and
OPN were combined in a logistic regression model,
sensitivity increased to 85% (95% CI: 74-96) and
speciﬁcity was 63% (95% CI: 52-74). At an optimal
combination of AFP at 20 ng/mL and of OPN at 149
ng/mL, the combination of OPN and AFP had a sen-
sitivity of 71% (95% CI: 57-86) and a speciﬁcity of
86% (95% CI: 79-94). For HCV patients, the per-
formance of OPN further increased (sensitivity, 82%;
95% CI: 66-98), whereas AFP performance decreased
(sensitivity, 46%; 95% CI: 25-67), when compared to
all HCCs. For early-stage HCC, OPN had, again, a
better performance than AFP, with a sensitivity of
75%, compared to 46% for AFP. When AFP and
OPN were combined for early-stage HCC, sensitivity
increased to 83% (95% CI: 69-98). At an optimal
OPN cut-off level of 149 ng/mL, the combination of
OPN and AFP had a sensitivity of 71% (95% CI: 53-
89) and a speciﬁcity of 86% (95% CI: 78-94) for
early-stage HCC.
To further validate the performance described above,
we performed a 10-fold cross-validation analysis for
the combination AFP and OPN (Supporting Table 2).
The average from 10 runs showed similar sensitivity
and speciﬁcity averages on classiﬁer calibration and
classiﬁer validation.
Circulating OPN Levels in HCC Patients From
Cohort 2. We subsequently analyzed OPN levels in an
independent cohort (Cohort 2) established in Thailand
and including a majority (59%) of HCC with CHB
and a majority of advanced HCC (Table 1). OPN lev-
els were measured blinded to clinical data in a total of
139 plasma samples collected from 91 HCC patients,
23 with cirrhosis or CHB, and 25 healthy controls.
Plasma levels of OPN were signiﬁcantly higher in
HCC patients, compared with all control groups.
OPN plasma levels were signiﬁcantly higher in HCC
(mean ¼ 565.8 ng/mL; P < 0.0001) than in cirrhosis
and CHB (89.2 ng/mL; P < 0.0001) and also greater
than in healthy controls (47.7 ng/mL; P < 0.0001)
(Fig. 4A).
Performance of OPN in Cohort 2. ROC analysis
was performed to evaluate the performance of OPN in
distinguishing HCC patients from patients with cir-
rhosis and chronic HBV. Overall, AFP performance
Table 1. Sensitivity and Speciﬁcity of AFP, OPN, and AFP1OPN in Cohort 1 Using AFP Clinical and
OPN Optimal Cut-off Values
Cohort 1 Cutoffs (ng/mL) Sensitivity (%) (95% CI) Speciﬁcity (%) (95% CI)
Cirrhosis versus HCC
AFP 20 53 (37-69) 93 (87-99)
OPN 91 74 (60-88) 66 (55-77)
AFPþOPN AFP ¼ 20 or OPN ¼ 91 85 (74-96) 63 (52-74)
AFPþOPN AFP ¼ 20 or OPN ¼ 149 71 (57-86) 86 (79-94)
HCV-Cirrhosis versus HCV-HCC
AFP 20 46 (25-67) 88 (79-98)
OPN 91 82 (66-98) 65 (51-79)
AFPþOPN AFP ¼ 20 or OPN ¼ 91 86 (72-100) 60 (46-75)
AFPþOPN AFP ¼ 20 or OPN ¼ 149 68 (49-88) 82 (70-93)
Cirrhosis versus early-stage HCC
AFP 20 46 (26-66) 93 (87-99)
OPN 91 75 (58-93) 62 (51-73)
AFPþOPN AFP ¼ 20 or OPN ¼ 91 83 (69-98) 63 (52-74)
AFPþOPN AFP ¼ 20 or OPN ¼ 149 71 (53-89) 86 (78-94)
Cirrhosis versus HCC (AFP <20 ng/mL)
OPN 91 65 (42-87) 68 (57-79)
AFP, alpha-fetoprotein; OPN, osteopontin; 95% CI, 95% conﬁdence interval; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
Fig. 2. Plasma levels of OPN among healthy individuals and those
with CHC, cirrhosis and HCC from Cohort 1. Box refers to the 25th and
75th percentile values, with a line indicating median levels, whereas the
interquartile range extends outside the box. Points outside the interquar-
tile range are outliers. HCC had higher OPN plasma levels, compared
with cirrhosis, CHC, and healthy control groups (P < 0.0001).
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was greater in this cohort, compared to Cohort 1, as
expected, because elevated levels of AFP was part of
the clinical algorithm for the detection of HCC. How-
ever, even with these diagnosis criteria and as observed
for Cohort 1, the AUC for OPN (0.93; 95% CI:
0.88-0.98) was higher than for AFP (0.86; 95% CI:
0.80-0.92) (Fig. 4B). The combination of AFP and
OPN had an even higher AUC than OPN alone
(0.96; 95% CI: 0.92-0.99). When only HBV-associ-
ated HCC patients were included, OPN AUC was
also higher (0.97; 95% CI: 0.94-1.00) than AFP AUC
(0.90; 95% CI: 0.84-0.97) (Fig. 4C). Finally, when
only HCC patients with AFP levels below 20 ng/mL
were included, OPN AUC remained high (0.87; 95%
CI: 0.75-0.99) (Fig. 4D).
The performance of OPN in these patient groups is
further described in Table 2. When using the currently
recommended clinical cutoff for AFP (20 ng/mL) and an
OPN cutoff of 91 ng/mL (determined based on Cohort
1 results), OPN had a better performance than AFP,
with a sensitivity of 93% (95% CI: 88-98), compared to
78% (95% CI: 70-86) for AFP. The best cutoff for
OPN, determined using the minimal distance to the
top-left corner in the ROC curve, was 156 ng/mL in
this cohort. When AFP at 20 ng/mL and OPN at 156
ng/mL were combined, sensitivity was 95% (95% CI:
90-99) and speciﬁcity was 96% (95% CI: 87-100). For
HBV patients, the performance of OPN alone was par-
ticularly high, with 95% sensitivity. At the OPN cut-off
level of 156 ng/mL, the combination of OPN and AFP
had a sensitivity of 96% and a speciﬁcity of 100%.
OPN Levels in Prediagnostic Samples. In a pilot
study, we investigated whether OPN levels would be
elevated in samples collected before HCC diagnosis in
patients enrolled in Cohort 1. At the time of the
study, a total of 22 cirrhosis patients with prospectively
collected blood specimens developed HCC during fol-
low-up. Among these 22 patients, 19 were diagnosed
with early- or very-early-stage HCC and 3 were diag-
nosed with intermediate-stage HCC (Supporting Table
3). At the time of diagnosis, only 8 of these 22
patients had AFP levels above 20 ng/mL, whereas 19
of them had OPN levels above 91 ng/mL, the optimal
cutoff determined by analysis of Cohort 1 samples
(Fig. 5A). Samples collected 6-12 months before diag-
nosis were available for 12 of these 22 patients; among
them, 2 patients had AFP levels above 20 ng/mL,
whereas 10 had OPN levels above 91 ng/mL (Fig.
Fig. 3. ROC curve evaluating those with HCC and cirrhosis controls in Cohort 1. The AUC is shown with its 95% CIs. (A) All cirrhosis versus
all HCC patients; (B) HCV-related cirrhosis versus HCV-related HCC; (C) cirrhosis versus early-stage HCC; and (D) cirrhosis versus HCC with AFP
levels below 20 ng/mL. AFP is represented by the solid line, OPN by the dash line, and the combination of AFP and OPN by the dotted line.
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5B). Samples collected 12-24 months before diagnosis
were available for 10 patients; among them, 1 had
AFP levels above 20 ng/mL and 6 had OPN levels
above 91 ng/mL (Fig. 5C). Altogether, 87% of these
patients had OPN levels above the cutoff within 2
years preceding HCC diagnosis. OPN values were
below 91 ng/mL in all samples collected more than 24
months before diagnosis (Fig. 5D). A similar analysis
was performed on 22 cirrhosis patients who did not
develop HCC during follow-up (data not shown). Me-
dian values of OPN in these patients were 54 ng/mL
at time 0, 60.5 ng/mL 6-12 months before, 54 ng/mL
12-24 months before, and 60 ng/mL 24-48 months
before, demonstrating the steady levels of OPN over
the years in these patients, in contrast to the progres-
sive increase of OPN levels in patients who developed
HCC during follow-up. Among these 22 cirrhotic
patients who did not develop HCC, 1 patient had
OPN values above 91 ng/mL in all 7 samples collected
over a period of 4 years. Another patient had OPN
values above 91 ng/mL at time 0 and 12 months
before, whereas all additional 4 samples collected 12-
53 months before had OPN values below 91 ng/mL.
It has to be noted that AFP was also above 20 ng/mL
in this patient at time 0.
Discussion
This study aimed at identifying novel biomarkers
for HCC surveillance in patients with cirrhosis and
represents a ﬁrst demonstration of the utility of using
plasma proteomic proﬁling to identify novel bio-
markers of early HCC. Comparative proteomic proﬁl-
ing of plasma obtained from patients with HCC or
cirrhosis identiﬁed higher levels of circulating OPN in
HCC. OPN is a secreted phosphoprotein that binds
alphaV-integrins and cluster of differentiation (CD)44
families of receptors.14 Elevated expression of OPN
has been associated with tumor invasion, progression,
or metastasis in multiple cancers,15 and OPN has been
proposed as a promising target for cancer therapy.16 In
HCC, an elevated plasma level of OPN is regarded as a
potential prognostic biomarker, and overexpression of
OPN is closely correlated with intrahepatic metastasis,
Fig. 4. Evaluation of OPN and AFP performance in HCC patients and patients with cirrhosis or CHB, enrolled in Cohort 2. (A) Plasma levels of OPN
in healthy controls, patients with cirrhosis, or CHB and HCC patients. Box refers to the 25th and 75th percentile values, with a line indicating median
levels, whereas the interquartile range extends outside the box. Points outside the interquartile range are outliers. (B) The AUC is shown, together with
the 95% CIs, for all cirrhosis and CHB versus HCC patients, (C) for HBV-related cirrhosis and CHB versus HBV-related HCC, and (D) for all cirrhosis
and CHB versus HCC patients with AFP levels below 20 ng/mL. Solid line: AFP; dash line: OPN; dotted line: combination of AFP and OPN.
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early recurrence, and a worse prognosis.17-20 This study
is, therefore, the ﬁrst demonstrating a potential utility of
OPN in early HCC detection. The utility of OPN in
early HCC detection may be relevant to recent reports
suggesting that beside its important role in metastasis,
OPN expression is also critical for tumor growth of
human HCC,21 and that down-regulation of OPN sup-
presses growth of HCC via induction of apoptosis.22
Overall, OPN sensitivity was better than AFP in
differentiating HCC cases from cirrhosis controls in
both cohorts included in this study and in all HCC
subgroups tested. The best performance was, however,
obtained by combining OPN and AFP. The combina-
tion of both markers enhanced sensitivity and speciﬁc-
ity in detecting HCC, indicating that these two
markers are complementary. An important goal in can-
cer surveillance is the detection of preclinical tumors.
Table 2. Sensitivity and Speciﬁcity of AFP, OPN, and AFP1OPN in Cohort 2 Using AFP Clinical and OPN
Optimal Cut-off Values
Cohort 2 Cutoffs (ng/mL)
Sensitivity (%) Speciﬁcity (%)
(95% CI) (95% CI)
Cirrhosis/CHB versus HCC
AFP 20 78 (70-86) 96 (87-100)
OPN 91 93 (88-98) 61 (41-81)
OPN 156 82 (75-90) 96 (87-100)
AFPþOPN AFP ¼ 20 or OPN ¼ 91 97 (93-100) 56 (36-77)
AFPþOPN AFP ¼ 20 or OPN ¼ 156 95 (90-99) 96 (87-100)
HBV-cirrhosis/CHB versus HBV-HCC
AFP 20 84 (74-94) 94 (82-100)
OPN 91 95 (88-100) 69 (46-92)
OPN 156 85 (76-95) 100 (—)
AFPþOPN AFP ¼ 20 or OPN ¼91 98 (95-100) 62 (39-86)
AFPþOPN AFP ¼ 20 or OPN ¼ 156 96 (92-100) 100 (—)
Cirrhosis/CHB versus HCC (AFP <20 ng/mL)
OPN 91 85 (69-100) 100 (—)
OPN 156 74 (55-93) 96 (88-100)
AFP, alpha-fetoprotein; OPN, osteopontin; 95% CI, 95% conﬁdence interval; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; HBV, hepatitis B virus.
Fig. 5. Plasma levels of OPN in prediagnosis samples. OPN was measured in plasma collected from 22 patients (A) at time of diagnosis, (B)
6-12 months before diagnosis, (C) 12-24 months before diagnosis, and (D) more than 24 months before diagnosis. Graphs also show levels of
AFP in the same samples. The dotted lines represent the cutoffs for AFP (20 ng/mL) and for OPN (91 ng/mL).
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In a pilot study, we showed that OPN values remained
intact for up to 2 years preceding HCC diagnosis.
This study is an important ﬁrst step in the evalua-
tion of OPN as a marker of early-stage HCC and rep-
resents a phase I/II study, as deﬁned by the guidelines
established by the NCI, for the development of bio-
markers for the early detection of cancer.23 A phase
I/II study consists of case-control studies to evaluate
the performance of a new marker, in this case OPN,
to diagnose early-stage cancer. As controls, we selected
patients with cirrhosis recommended for surveillance,
which is the design suggested by the NCI’s guidelines
for biomarker development. Such phase I or II studies
are critical to appropriately design prospective studies
for the early detection of HCC. Overall, we showed
that OPN is a marker of early-stage HCC and com-
plements AFP in a small validation study. In addition,
the performance of OPN was evaluated in two distinct
patient populations with different disease etiologies.
This study had, however, some limitations, such as the
small sample size in the patient subgroups and the fact
that the patients in Cohort 2 were, in part, diagnosed
using AFP, therefore creating a bias in favor of AFP
performance in this cohort. This study was also per-
formed in plasma collected using a standardized proto-
col. Further analysis will be needed to determine fac-
tors in sample preparation and analysis that might
affect the performance of OPN. The next step is a
large-scale validation in a phase II study that will also
include the analysis of OPN against other currently
used markers, such AFP-L3 and DCP, and integration
of long-term outcome data. This will be followed by a
phase III prospective study aimed at determining
whether OPN alone or in combination with AFP
complements US as a screening test to ﬁnd lesions
that have a high likelihood of cure or whether OPN is
a useful marker for risk stratiﬁcation.
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